[{"edinetCode":"E00948","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1767.0,"averageTemporaryStaff":139.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":19310000.0,"sharesOwendPercent":0.3635,"outstandingShares":null,"numberOfSubsidiary":13.0,"bps":1192.73,"equityRatio":0.554,"cashAndCashEquivalents":9118652000.0,"assets":114358000000.0,"currentAssets":38764995000.0,"fixedAsset":75592673000.0,"tangibleFixedAssets":24154328000.0,"intangibleFixedAssets":33884992000.0,"investmentAndOtherAssets":17553351000.0,"liabilities":50853021000.0,"currentLiabilities":45178025000.0,"shorTermDept":33061728000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":5674996000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2884150000.0,"netAsset":63504646000.0,"capitalStock":57928123000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":39654887000.0,"treasuryStock":-5283000.0,"valuationAndConversionAdjustments":5423648000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":64849813000.0,"costOfSales":18168981000.0,"grossProfit":46680831000.0,"sgaExpenses":42149617000.0,"salaryAndBenefit":7723188000.0,"depreciationAndSGA":null,"RDExpenses":8458870000.0,"operatingIncome":4541582000.0,"nonOperatingIncome":337258000.0,"nonOperatingExpenses":440529000.0,"interestExpense":267169000.0,"ordinaryProfit":4438311000.0,"extraordinaryGain":810451000.0,"extraordinaryLoss":327928000.0,"incomeBeforeTax":4920834000.0,"incomeTaxes":1344953000.0,"netIncome":3575880000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3544359000.0,"comprehensiveIncome":1686051000.0,"eps":66.73,"dilutedEps":null,"dividendPerShare":null,"per":25.7,"roe":0.056,"cashFlowFromOperatingActivities":7238497000.0,"depreciationAndCashflowFromOperatingActivities":3106174000.0,"cashFlowFromInvestingActivities":-703347000.0,"cashFlowFromFinancialActivities":-8982569000.0,"changesInCashAndCashEquivalents":-3092335000.0,"列1":"asr","submitDate":"2017\/6\/29","stockCode":4559,"accountingYear":"第63期(自　平成28年４月１日　至　平成29年３月31日)","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1753.0,"averageTemporaryStaff":135.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":18991000.0,"sharesOwendPercent":0.377,"outstandingShares":null,"numberOfSubsidiary":13.0,"bps":1300.88,"equityRatio":0.565,"cashAndCashEquivalents":10034779000.0,"assets":116086000000.0,"currentAssets":39255720000.0,"fixedAsset":76830634000.0,"tangibleFixedAssets":23340763000.0,"intangibleFixedAssets":32337633000.0,"investmentAndOtherAssets":21152236000.0,"liabilities":50390195000.0,"currentLiabilities":36159637000.0,"shorTermDept":24926395000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":14230557000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":8676175000.0,"netAsset":65696159000.0,"capitalStock":54773853000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":42096195000.0,"treasuryStock":-5600862000.0,"valuationAndConversionAdjustments":10758583000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":64568681000.0,"costOfSales":18341890000.0,"grossProfit":46226790000.0,"sgaExpenses":41405409000.0,"salaryAndBenefit":7730903000.0,"depreciationAndSGA":null,"RDExpenses":7331914000.0,"operatingIncome":4830399000.0,"nonOperatingIncome":490128000.0,"nonOperatingExpenses":231397000.0,"interestExpense":195348000.0,"ordinaryProfit":5089130000.0,"extraordinaryGain":691142000.0,"extraordinaryLoss":203000000.0,"incomeBeforeTax":5577271000.0,"incomeTaxes":1394245000.0,"netIncome":4183026000.0,"netIncomeAttributableToOwnersOfTheParentCompany":4157810000.0,"comprehensiveIncome":9510812000.0,"eps":80.72,"dilutedEps":null,"dividendPerShare":null,"per":26.4,"roe":0.065,"cashFlowFromOperatingActivities":8821935000.0,"depreciationAndCashflowFromOperatingActivities":3142560000.0,"cashFlowFromInvestingActivities":1563940000.0,"cashFlowFromFinancialActivities":-9628933000.0,"changesInCashAndCashEquivalents":916127000.0,"列1":"asr","submitDate":"2018\/6\/28","stockCode":4559,"accountingYear":"第64期(自　平成29年４月１日　至　平成30年３月31日)","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1705.0,"averageTemporaryStaff":136.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":18207000.0,"sharesOwendPercent":0.38,"outstandingShares":null,"numberOfSubsidiary":13.0,"bps":1235.09,"equityRatio":0.536,"cashAndCashEquivalents":7920049000.0,"assets":110434000000.0,"currentAssets":38723292000.0,"fixedAsset":71710566000.0,"tangibleFixedAssets":22913693000.0,"intangibleFixedAssets":29799297000.0,"investmentAndOtherAssets":18997575000.0,"liabilities":51086030000.0,"currentLiabilities":38838546000.0,"shorTermDept":27988804000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":12247483000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":7795965000.0,"netAsset":59347828000.0,"capitalStock":51534715000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":43822190000.0,"treasuryStock":-10565994000.0,"valuationAndConversionAdjustments":7650871000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":61831578000.0,"costOfSales":17752655000.0,"grossProfit":44078923000.0,"sgaExpenses":40334037000.0,"salaryAndBenefit":7590954000.0,"depreciationAndSGA":null,"RDExpenses":6832020000.0,"operatingIncome":3737067000.0,"nonOperatingIncome":290921000.0,"nonOperatingExpenses":732091000.0,"interestExpense":199645000.0,"ordinaryProfit":3295897000.0,"extraordinaryGain":1984655000.0,"extraordinaryLoss":59539000.0,"incomeBeforeTax":5221014000.0,"incomeTaxes":1757208000.0,"netIncome":3463805000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3454098000.0,"comprehensiveIncome":350429000.0,"eps":69.56,"dilutedEps":null,"dividendPerShare":null,"per":27.5,"roe":0.055,"cashFlowFromOperatingActivities":5500730000.0,"depreciationAndCashflowFromOperatingActivities":3032752000.0,"cashFlowFromInvestingActivities":-2855903000.0,"cashFlowFromFinancialActivities":-4534606000.0,"changesInCashAndCashEquivalents":-2114730000.0,"列1":"asr","submitDate":"2019\/6\/27","stockCode":4559,"accountingYear":"第65期(自　2018年４月１日　至　2019年３月31日)","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.516,"cashAndCashEquivalents":null,"assets":110102000000.0,"currentAssets":38042754000.0,"fixedAsset":72059093000.0,"tangibleFixedAssets":23417733000.0,"intangibleFixedAssets":29170235000.0,"investmentAndOtherAssets":19471124000.0,"liabilities":53131894000.0,"currentLiabilities":39893483000.0,"shorTermDept":29034165000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":13238410000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":8193975000.0,"netAsset":56969954000.0,"capitalStock":49802674000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":44153810000.0,"treasuryStock":-12629655000.0,"valuationAndConversionAdjustments":7006968000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":15113964000.0,"costOfSales":4269190000.0,"grossProfit":10844774000.0,"sgaExpenses":9512072000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1329738000.0,"nonOperatingIncome":322942000.0,"nonOperatingExpenses":95776000.0,"interestExpense":50763000.0,"ordinaryProfit":1556904000.0,"extraordinaryGain":123000.0,"extraordinaryLoss":604000.0,"incomeBeforeTax":1556422000.0,"incomeTaxes":408595000.0,"netIncome":1147827000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1146261000.0,"comprehensiveIncome":502752000.0,"eps":24.14,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/7","stockCode":4559,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":17821000.0,"sharesOwendPercent":0.384,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.513,"cashAndCashEquivalents":7858335000.0,"assets":107807000000.0,"currentAssets":36453413000.0,"fixedAsset":71353336000.0,"tangibleFixedAssets":23104450000.0,"intangibleFixedAssets":28484547000.0,"investmentAndOtherAssets":19764338000.0,"liabilities":52352836000.0,"currentLiabilities":40527399000.0,"shorTermDept":30406545000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":11825437000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":6902680000.0,"netAsset":55453913000.0,"capitalStock":48874417000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":44237912000.0,"treasuryStock":-13642015000.0,"valuationAndConversionAdjustments":6424165000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":30317539000.0,"costOfSales":8555897000.0,"grossProfit":21761642000.0,"sgaExpenses":20021929000.0,"salaryAndBenefit":3634307000.0,"depreciationAndSGA":null,"RDExpenses":3264671000.0,"operatingIncome":1738990000.0,"nonOperatingIncome":214043000.0,"nonOperatingExpenses":324698000.0,"interestExpense":103761000.0,"ordinaryProfit":1628334000.0,"extraordinaryGain":291000.0,"extraordinaryLoss":1436000.0,"incomeBeforeTax":1627190000.0,"incomeTaxes":395017000.0,"netIncome":1232172000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1230363000.0,"comprehensiveIncome":-937000.0,"eps":26.16,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":2335743000.0,"depreciationAndCashflowFromOperatingActivities":1631334000.0,"cashFlowFromInvestingActivities":-79335000.0,"cashFlowFromFinancialActivities":-2159480000.0,"changesInCashAndCashEquivalents":-61714000.0,"列1":"q2r","submitDate":"2019\/11\/6","stockCode":4559,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.503,"cashAndCashEquivalents":null,"assets":108811000000.0,"currentAssets":37388971000.0,"fixedAsset":71422286000.0,"tangibleFixedAssets":23292320000.0,"intangibleFixedAssets":27640622000.0,"investmentAndOtherAssets":20489344000.0,"liabilities":53871028000.0,"currentLiabilities":41619092000.0,"shorTermDept":30960479000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":12251935000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":6700000000.0,"netAsset":54940229000.0,"capitalStock":48883106000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":44247039000.0,"treasuryStock":-13642453000.0,"valuationAndConversionAdjustments":5898748000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":46303932000.0,"costOfSales":12755300000.0,"grossProfit":33548631000.0,"sgaExpenses":30155621000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":3382741000.0,"nonOperatingIncome":282080000.0,"nonOperatingExpenses":577864000.0,"interestExpense":157807000.0,"ordinaryProfit":3086957000.0,"extraordinaryGain":20764000.0,"extraordinaryLoss":1473000.0,"incomeBeforeTax":3106247000.0,"incomeTaxes":761449000.0,"netIncome":2344798000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2339911000.0,"comprehensiveIncome":586213000.0,"eps":49.98,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/7","stockCode":4559,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1667.0,"averageTemporaryStaff":134.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":18056000.0,"sharesOwendPercent":0.39,"outstandingShares":null,"numberOfSubsidiary":14.0,"bps":1134.3,"equityRatio":0.504,"cashAndCashEquivalents":8880252000.0,"assets":104156000000.0,"currentAssets":35020004000.0,"fixedAsset":69135859000.0,"tangibleFixedAssets":23125436000.0,"intangibleFixedAssets":29848418000.0,"investmentAndOtherAssets":16162004000.0,"liabilities":51477017000.0,"currentLiabilities":41070248000.0,"shorTermDept":29705195000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":10406768000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":5470705000.0,"netAsset":52678846000.0,"capitalStock":49264416000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":44832502000.0,"treasuryStock":-13846605000.0,"valuationAndConversionAdjustments":3246045000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":60426743000.0,"costOfSales":16643613000.0,"grossProfit":43783130000.0,"sgaExpenses":39696793000.0,"salaryAndBenefit":7582493000.0,"depreciationAndSGA":null,"RDExpenses":6342731000.0,"operatingIncome":4094824000.0,"nonOperatingIncome":310398000.0,"nonOperatingExpenses":525879000.0,"interestExpense":228637000.0,"ordinaryProfit":3879343000.0,"extraordinaryGain":44605000.0,"extraordinaryLoss":3670000.0,"incomeBeforeTax":3920277000.0,"incomeTaxes":981467000.0,"netIncome":2938810000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2925375000.0,"comprehensiveIncome":-1471021000.0,"eps":62.62,"dilutedEps":null,"dividendPerShare":null,"per":33.3,"roe":0.052,"cashFlowFromOperatingActivities":7251345000.0,"depreciationAndCashflowFromOperatingActivities":3255655000.0,"cashFlowFromInvestingActivities":-405119000.0,"cashFlowFromFinancialActivities":-5877764000.0,"changesInCashAndCashEquivalents":916365000.0,"列1":"asr","submitDate":"2020\/6\/26","stockCode":4559,"accountingYear":"第66期(自　2019年４月１日　至　2020年３月31日)","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.496,"cashAndCashEquivalents":null,"assets":106753000000.0,"currentAssets":36634893000.0,"fixedAsset":70118359000.0,"tangibleFixedAssets":24136460000.0,"intangibleFixedAssets":29313014000.0,"investmentAndOtherAssets":16668883000.0,"liabilities":53649061000.0,"currentLiabilities":42660753000.0,"shorTermDept":33523365000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":10988307000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":6179210000.0,"netAsset":53104191000.0,"capitalStock":49142628000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":45019680000.0,"treasuryStock":-14155572000.0,"valuationAndConversionAdjustments":3795588000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":13331638000.0,"costOfSales":3876204000.0,"grossProfit":9455433000.0,"sgaExpenses":8397533000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1060051000.0,"nonOperatingIncome":224271000.0,"nonOperatingExpenses":649944000.0,"interestExpense":59037000.0,"ordinaryProfit":634378000.0,"extraordinaryGain":675638000.0,"extraordinaryLoss":597000.0,"incomeBeforeTax":1309419000.0,"incomeTaxes":336073000.0,"netIncome":973345000.0,"netIncomeAttributableToOwnersOfTheParentCompany":974163000.0,"comprehensiveIncome":1521296000.0,"eps":21.05,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/7","stockCode":4559,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":18058000.0,"sharesOwendPercent":0.3914,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.502,"cashAndCashEquivalents":8988321000.0,"assets":106378000000.0,"currentAssets":36752028000.0,"fixedAsset":69625521000.0,"tangibleFixedAssets":23816770000.0,"intangibleFixedAssets":28715676000.0,"investmentAndOtherAssets":17093074000.0,"liabilities":52818893000.0,"currentLiabilities":42902783000.0,"shorTermDept":34848971000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":9916109000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":4866800000.0,"netAsset":53558656000.0,"capitalStock":49556926000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":45434134000.0,"treasuryStock":-14155728000.0,"valuationAndConversionAdjustments":3838112000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":26809262000.0,"costOfSales":7648896000.0,"grossProfit":19160365000.0,"sgaExpenses":17558361000.0,"salaryAndBenefit":3567524000.0,"depreciationAndSGA":null,"RDExpenses":2529124000.0,"operatingIncome":1598585000.0,"nonOperatingIncome":274288000.0,"nonOperatingExpenses":565317000.0,"interestExpense":117613000.0,"ordinaryProfit":1307556000.0,"extraordinaryGain":672762000.0,"extraordinaryLoss":1317000.0,"incomeBeforeTax":1979001000.0,"incomeTaxes":589426000.0,"netIncome":1389574000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1388617000.0,"comprehensiveIncome":1979273000.0,"eps":30.05,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":1209070000.0,"depreciationAndCashflowFromOperatingActivities":1819336000.0,"cashFlowFromInvestingActivities":-4347881000.0,"cashFlowFromFinancialActivities":3167114000.0,"changesInCashAndCashEquivalents":108069000.0,"列1":"q2r","submitDate":"2020\/11\/11","stockCode":4559,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.452,"cashAndCashEquivalents":null,"assets":119940000000.0,"currentAssets":51853125000.0,"fixedAsset":68087166000.0,"tangibleFixedAssets":23824081000.0,"intangibleFixedAssets":28516453000.0,"investmentAndOtherAssets":15746630000.0,"liabilities":65512578000.0,"currentLiabilities":55874227000.0,"shorTermDept":46699320000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":9638351000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":4973200000.0,"netAsset":54427713000.0,"capitalStock":50717372000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":46947375000.0,"treasuryStock":-14508523000.0,"valuationAndConversionAdjustments":3549504000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":42374640000.0,"costOfSales":11916625000.0,"grossProfit":30458014000.0,"sgaExpenses":26589361000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":3856962000.0,"nonOperatingIncome":352991000.0,"nonOperatingExpenses":671410000.0,"interestExpense":169973000.0,"ordinaryProfit":3538543000.0,"extraordinaryGain":1053223000.0,"extraordinaryLoss":1329000.0,"incomeBeforeTax":4590437000.0,"incomeTaxes":903031000.0,"netIncome":3687405000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3686220000.0,"comprehensiveIncome":3985465000.0,"eps":79.83,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/9","stockCode":4559,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1690.0,"averageTemporaryStaff":136.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":18237000.0,"sharesOwendPercent":0.3991,"outstandingShares":null,"numberOfSubsidiary":15.0,"bps":1225.69,"equityRatio":0.46,"cashAndCashEquivalents":9668938000.0,"assets":121859000000.0,"currentAssets":37313049000.0,"fixedAsset":84546287000.0,"tangibleFixedAssets":23634282000.0,"intangibleFixedAssets":42069811000.0,"investmentAndOtherAssets":18842193000.0,"liabilities":65679373000.0,"currentLiabilities":53757037000.0,"shorTermDept":44158858000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":11922336000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":5819600000.0,"netAsset":56179963000.0,"capitalStock":49661757000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":46380939000.0,"treasuryStock":-14997702000.0,"valuationAndConversionAdjustments":6350802000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":55442073000.0,"costOfSales":15796879000.0,"grossProfit":39645193000.0,"sgaExpenses":36192768000.0,"salaryAndBenefit":7763021000.0,"depreciationAndSGA":null,"RDExpenses":5411673000.0,"operatingIncome":3442076000.0,"nonOperatingIncome":373371000.0,"nonOperatingExpenses":640435000.0,"interestExpense":238195000.0,"ordinaryProfit":3175011000.0,"extraordinaryGain":1058749000.0,"extraordinaryLoss":310856000.0,"incomeBeforeTax":3922905000.0,"incomeTaxes":791409000.0,"netIncome":3131495000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3119785000.0,"comprehensiveIncome":6226872000.0,"eps":67.72,"dilutedEps":null,"dividendPerShare":null,"per":31.1,"roe":0.057,"cashFlowFromOperatingActivities":6894290000.0,"depreciationAndCashflowFromOperatingActivities":3748527000.0,"cashFlowFromInvestingActivities":-17460812000.0,"cashFlowFromFinancialActivities":11185277000.0,"changesInCashAndCashEquivalents":788686000.0,"列1":"asr","submitDate":"2021\/6\/29","stockCode":4559,"accountingYear":"第67期(自　2020年４月１日　至　2021年３月31日)","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.445,"cashAndCashEquivalents":null,"assets":123111000000.0,"currentAssets":39845390000.0,"fixedAsset":83265351000.0,"tangibleFixedAssets":23351076000.0,"intangibleFixedAssets":41462142000.0,"investmentAndOtherAssets":18452132000.0,"liabilities":68198152000.0,"currentLiabilities":55637711000.0,"shorTermDept":45373059000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":12560441000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":6143500000.0,"netAsset":54912588000.0,"capitalStock":49594952000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":47075177000.0,"treasuryStock":-15758744000.0,"valuationAndConversionAdjustments":5139178000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":13548962000.0,"costOfSales":4250003000.0,"grossProfit":9298958000.0,"sgaExpenses":8047156000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1251802000.0,"nonOperatingIncome":908152000.0,"nonOperatingExpenses":78570000.0,"interestExpense":69921000.0,"ordinaryProfit":2081384000.0,"extraordinaryGain":3719000.0,"extraordinaryLoss":2061000.0,"incomeBeforeTax":2083041000.0,"incomeTaxes":671324000.0,"netIncome":1411717000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1408956000.0,"comprehensiveIncome":211820000.0,"eps":30.91,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/10","stockCode":4559,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":20028000.0,"sharesOwendPercent":0.4441,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.455,"cashAndCashEquivalents":10274703000.0,"assets":123673000000.0,"currentAssets":39698535000.0,"fixedAsset":83974800000.0,"tangibleFixedAssets":23193284000.0,"intangibleFixedAssets":41383945000.0,"investmentAndOtherAssets":19397570000.0,"liabilities":67256956000.0,"currentLiabilities":48527856000.0,"shorTermDept":39246121000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":18729099000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":12271460000.0,"netAsset":56416379000.0,"capitalStock":49823244000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":47782212000.0,"treasuryStock":-16237488000.0,"valuationAndConversionAdjustments":6412384000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":28606173000.0,"costOfSales":8462724000.0,"grossProfit":20143448000.0,"sgaExpenses":17470923000.0,"salaryAndBenefit":3950603000.0,"depreciationAndSGA":null,"RDExpenses":2986570000.0,"operatingIncome":2672525000.0,"nonOperatingIncome":609211000.0,"nonOperatingExpenses":165000000.0,"interestExpense":148520000.0,"ordinaryProfit":3116736000.0,"extraordinaryGain":6837000.0,"extraordinaryLoss":3995000.0,"incomeBeforeTax":3119578000.0,"incomeTaxes":998954000.0,"netIncome":2120624000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2115992000.0,"comprehensiveIncome":2194411000.0,"eps":46.65,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":3111463000.0,"depreciationAndCashflowFromOperatingActivities":2321125000.0,"cashFlowFromInvestingActivities":-1696780000.0,"cashFlowFromFinancialActivities":-1082036000.0,"changesInCashAndCashEquivalents":476334000.0,"列1":"q2r","submitDate":"2021\/11\/8","stockCode":4559,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0},{"edinetCode":"E00948","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.439,"cashAndCashEquivalents":null,"assets":125982000000.0,"currentAssets":43434908000.0,"fixedAsset":82546953000.0,"tangibleFixedAssets":23071345000.0,"intangibleFixedAssets":40465844000.0,"investmentAndOtherAssets":19009763000.0,"liabilities":70485593000.0,"currentLiabilities":46498689000.0,"shorTermDept":35823636000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":23986904000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":17391820000.0,"netAsset":55496267000.0,"capitalStock":50855382000.0,"capital":6593398000.0,"capitalSurplus":11685121000.0,"accumulatedEarnings":48943101000.0,"treasuryStock":-16366239000.0,"valuationAndConversionAdjustments":4457619000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":45104773000.0,"costOfSales":13279666000.0,"grossProfit":31825106000.0,"sgaExpenses":26329373000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":5495732000.0,"nonOperatingIncome":399376000.0,"nonOperatingExpenses":281916000.0,"interestExpense":232304000.0,"ordinaryProfit":5613192000.0,"extraordinaryGain":18072000.0,"extraordinaryLoss":4002000.0,"incomeBeforeTax":5627262000.0,"incomeTaxes":1578735000.0,"netIncome":4048526000.0,"netIncomeAttributableToOwnersOfTheParentCompany":4043589000.0,"comprehensiveIncome":2169784000.0,"eps":89.33,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/4","stockCode":4559,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00948","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":6593,"settlementDate":"2022\/3\/31","submitterName":"ゼリア新薬工業株式会社","submitterNameEnglish":"ZERIA PHARMCEUTICAL CO., LTD.","submitterNameKana":"ゼリアシンヤクコウギョウカブシキガイシャ","location":"中央区日本橋小舟町１０番１１号","industory":"医薬品","corporateNumber":7010000000000.0}]